Drugs / AZD3470
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06137144 | Jan 2024 → May 2029 expected | Hodgkins lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma, not otherwise specified | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06130553 | Jan 2024 → Dec 2028 expected | — | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD3470 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06130553 ↗ |
| Action | Inhibit | “inhibitor of PRMT5” NCT06130553 ↗ |
| Modality | Small molecule | “small molecule inhibitor” NCT06137144 ↗ |
| Route | Oral | “following oral administration of AZD3470” NCT06137144 ↗ |
| Target | PRMT5 | “inhibitor of PRMT5” NCT06130553 ↗ |